An approach to the new psychoactive drugs phenomenon

Las nuevas drogas psicoactivas (NDP) son aquellas que, aun cuando representan un peligro para la salud publica, no estan prohibidas por los acuerdos internacionales sobre narcoticos. La nocion incluye tambien nuevos contextos de usos, nuevas formas de administracion y nuevas vias de distribucion, entre las que destaca Internet. Los riesgos asociados al consumo de NDP son en gran medida desconocidos por los usuarios y el personal de salud. Objetivo. Integrar la informacion existente sobre las principales NDP en cuanto a su descripcion, psicofarmacologia, epidemiologia, efectos psicoactivos y complicaciones medicas descritas. Metodo. Revision de la informacion actualizada de relevancia clinica sobre las NDP obtenida de libros especializados y revistas cientificas indexadas (PubMed/Medline, Google Scholar, Scopus); de documentos oficiales de organismos internacionales dedicados a la epidemiologia del consumo de drogas, y de portales y foros en Internet gestionados por usuarios de sustancias psicoactivas. Resultados. Se describen de manera detallada aspectos de interes clinico y farmacologico, asi como datos epidemiologicos y riesgos asociados al consumo de las NDP mas relevantes: cannabinoides sinteticos, catinonas sinteticas, serie de los NBOMe, indolaminas, piperazinas, hongos alucinogenos (Psilocybe sp.), opioides sinteticos, productos vegetales (khat, kratom, Salvia divinorum, ayahuasca) y anestesicos disociativos. Discusion y conclusion. El surgimiento de las NDP es un fenomeno en auge con importantes consecuencias en la salud publica. Se hace imprescindible para el profesional medico conocer las nuevas tendencias en el consumo y los riesgos potenciales del mismo. Son necesarias tambien nuevas investigaciones para comprender el fenomeno de las NDP y sus implicaciones farmacologicas, clinicas y legales

• Publication year

  2017

• Venue

  Salud Mental

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers
  DOI 10.17711/sm.0185-3325.2017.010
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.

  2016cited by this paper
• Severe Psychosis, Drug Dependence, and Hepatitis C Related to Slamming Mephedrone

  2016cited by this paper
• Hepatotoxicity of piperazine designer drugs: up-regulation of key enzymes of cholesterol and lipid biosynthesis

  2016cited by this paper
• [Vegetables as new psychoactive drugs: a narrative review].

  2016cited by this paper
• Synthetic cannabinoid use in a nationally representative sample of US high school seniors.

  2015influential reference
• 25I-NBOMe related death in Australia: a case report.

  2015cited by this paper
• Novel psychoactive substances of interest for psychiatry

  2015cited by this paper
• Intoxications by the dissociative new psychoactive substances diphenidine and methoxphenidine

  2015cited by this paper
• Impact of a synthetic cannabinoid (CP-47,497-C8) on protein expression in human cells: evidence for induction of inflammation and DNA damage

  2015cited by this paper
• Toxicology and Management of Novel Psychoactive Drugs

  2015cited by this paper
• “Word of Mouse”: Indigenous Harm Reduction and Online Consumerism of the Synthetic Compound Methoxphenidine

  2015cited by this paper
• First reported fatalities associated with the 'research chemical' 2-methoxydiphenidine.

  2015cited by this paper
• Psyclones: a roller coaster of life? Hidden synthetic cannabinoids and stimulants in apparently harmless products

  2015cited by this paper
• AH-7921: a new synthetic opioid of abuse.

  2015cited by this paper
• Prevalence of use and acute toxicity associated with the use of NBOMe drugs

  2015cited by this paper
• Next generation of novel psychoactive substances on the horizon - A complex problem to face.

  2015influential reference
• The Association of Salvia divinorum and Psychotic Disorders: A Review of the Literature and Case Series

  2015cited by this paper
• Understanding the availability, prevalence of use, desired effects, acute toxicity and dependence potential of the novel opioid MT-45

  2015cited by this paper
• NBOMe: new potent hallucinogens--pharmacology, analytical methods, toxicities, fatalities: a review.

  2015cited by this paper
• The interest in eight new psychoactive substances before and after scheduling.

  2015cited by this paper
• Psychedelics as medicines for substance abuse rehabilitation: evaluating treatments with LSD, Peyote, Ibogaine and Ayahuasca.

  2015cited by this paper
• A fatal poisoning involving 25C-NBOMe.

  2015cited by this paper
• The hallucinogenic world of tryptamines: an updated review

  2015cited by this paper
• Recent advances in the neuropsychopharmacology of serotonergic hallucinogens.

  2015cited by this paper
• New psychoactive substances as adulterants of controlled drugs. A worrying phenomenon?

  2014cited by this paper
• Serotonin syndrome.

  2014cited by this paper
• Pathological Findings in 2 Cases of Fatal 25I-NBOMe Toxicity

  2014cited by this paper
• Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users.

  2014cited by this paper
• Psychoactive natural products: overview of recent developments.

  2014cited by this paper
• Psilocybin--summary of knowledge and new perspectives.

  2014cited by this paper
• The claustrum’s proposed role in consciousness is supported by the effect and target localization of Salvia divinorum

  2014cited by this paper
• Postmortem detection of 25I-NBOMe [2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death.

  2014cited by this paper
• Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications.

  2014cited by this paper
• 25C-NBOMe: Preliminary Data on Pharmacology, Psychoactive Effects, and Toxicity of a New Potent and Dangerous Hallucinogenic Drug

  2014cited by this paper
• Raising awareness of new psychoactive substances: chemical analysis and in vitro toxicity screening of ‘legal high’ packages containing synthetic cathinones

  2014cited by this paper
• 'Krokodil'--a designer drug from across the Atlantic, with serious consequences.

  2014cited by this paper
• Is there something more about synthetic cannabinoids?

  2014cited by this paper
• The NBOMe hallucinogenic drug series: Patterns of use, characteristics of users and self-reported effects in a large international sample

  2014cited by this paper
• Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users.

  2014cited by this paper
• MT-45, a new psychoactive substance associated with hearing loss and unconsciousness

  2014cited by this paper
• Recreational drug discovery: natural products as lead structures for the synthesis of smart drugs.

  2014cited by this paper
• Use of Synthetic Cannabinoids in Patients With Psychotic Disorders: Case Series

  2014cited by this paper
• Panorama actual en el uso de drogas emergentes

  2014cited by this paper
• URB-754: a new class of designer drug and 12 synthetic cannabinoids detected in illegal products.

  2013cited by this paper
• Epidemiology of adolescent Salvia divinorum use in Canada.

  2013influential reference
• The impact of the prohibition of benzylpiperazine (BZP) 'legal highs' on the prevalence of BZP, new legal highs and other drug use in New Zealand.

  2013influential reference
• Promoting innovation and excellence to face the rapid diffusion of Novel Psychoactive Substances in the EU: the outcomes of the ReDNet project

  2013cited by this paper
• Methoxetamine (MXE) – A Phenomenological Study of Experiences Induced by a “Legal High” from the Internet

  2013cited by this paper
• Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings.

  2013cited by this paper
• 25C-NBOMe--new potent hallucinogenic substance identified on the drug market.

  2013cited by this paper
• From “Special K” to “Special M”: The Evolution of the Recreational Use of Ketamine and Methoxetamine

  2013cited by this paper
• e-Psychonauts: Conducting research in online drug forum communities

  2012cited by this paper
• Comparative neuropharmacology of three psychostimulant cathinone derivatives: butylone, mephedrone and methylone

  2012cited by this paper
• Mitragyna speciosa use in the northern states of Malaysia: a cross-sectional study.

  2012cited by this paper
• The Designer Methcathinone Analogs, Mephedrone and Methylone, are Substrates for Monoamine Transporters in Brain Tissue

  2012cited by this paper
• "Spice" and "K2" herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans.

  2012cited by this paper
• "Legal highs" on the net-Evaluation of UK-based Websites, products and product information.

  2011cited by this paper
• Drogas emergentes: una perspectiva medicolegal

  2011cited by this paper
• Mephedrone (4-methylmethcathinone; ‘meow meow’): chemical, pharmacological and clinical issues

  2011cited by this paper
• Experiences with mephedrone pre- and post-legislative controls: perceptions of safety and sources of supply.

  2011cited by this paper
• Beyond THC: The New Generation of Cannabinoid Designer Drugs

  2011cited by this paper
• Chemistry, Pharmacology, and Toxicology of Khat (Catha Edulis Forsk): A Review

  2011cited by this paper
• Khat use and monitoring drug use in Europe: the current situation and issues for the future.

  2010cited by this paper
• Inhibition of monoamine oxidase activity by cannabinoids

  2010influential reference
• Spice drugs as a new trend: mode of action, identification and legislation.

  2010cited by this paper
• Withdrawal phenomena and dependence syndrome after the consumption of "spice gold".

  2009cited by this paper
• The behavioral pharmacology of hallucinogens.

  2008cited by this paper
• Khat use as risk factor for psychotic disorders: A cross-sectional and case-control study in Somalia

  2005cited by this paper
• Hallucinogen persisting perception disorder after psilocybin consumption: a case study

  2005cited by this paper
• Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose–effect study

  2004cited by this paper
• Special K

  2003cited by this paper
• Human Pharmacology of Ayahuasca: Subjective and Cardiovascular Effects, Monoamine Metabolite Excretion, and Pharmacokinetics

  2003cited by this paper
• PIHKAL, a chemical love story.

  1999cited by this paper
• Tihkal : The Continuation

  1997cited by this paper
• New psychoactive drugs.

  1985cited by this paper
• Pharmacological aspects of the chewing of khat leaves.

  1985cited by this paper

• Drogas emergentes: detección mediante sensores electroquímicos

  2024cites this paper
• Pharmaco-Toxicological Effects of Atypical Synthetic Cathinone Mephtetramine (MTTA) in Mice: Possible Reasons for Its Brief Appearance over NPSs Scene

  2023cites this paper
• Genotoxicity Evaluation of The Novel Psychoactive Substance MTTA

  2023cites this paper
• Neuropathology of Drug Abuse

  2021cites this paper
• Basic Substance Characteristics and Neuropathological Findings in Drug Abusers

  2020cites this paper
• Interpol review of controlled substances 2016–2019☆

  2020cites this paper
• Synthetic cathinones: an evolving class of new psychoactive substances

  2019cites this paper
• The control of synthetic cannabinoids potentiates the toxicity of emerging substances

  2019cites this paper
• Assessing the content of a synthetic cannabinoid “research chemical” package

  2019cites this paper
• Screening for new psychoactive substances (NPS) without reference standards on high resolution mass spectrometers (HR-MS)

  2019cites this paper
• “Flakka” Intoxication: What have We Learned?

  2018cites this paper
• A narrative review of the naturally occurring inhibitory neurotransmitter gamma-aminobutyric acid (GABA) called phenibut in dietary supplements

  2018cites this paper
• Para una ética de la estructuración farmacológica de las relaciones sociales

  2018cites this paper
• Pharmacotoxicology of Non-fentanyl Derived New Synthetic Opioids

  2018influential citation